Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract: There is provided a series of novel phenylcarboxyamides of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and Y as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Abstract: This invention provides Compounds I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS.

Abstract: A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.

Abstract: A method for obtaining an immunogenic strain useful for producing a vaccine against Coccidiosis comprises the cycle of infecting at least one first group of specific pathogen-free donor birds with oocysts from an Eimeria species. Blood is then collected from these donor birds, and is then used to infect a second group of specific pathogen-free birds. Oocysts are collected from the second group of birds. These oocysts are then multiplicated to complete the cycle. The cycle is then repeated using the multiplicated oocysts. After a total of about three cycles, a final antigen may be harvested and utilized as a source to generate oocysts for a vaccine.

Abstract: A process to excystate protozoal sporocysts involves treatment of an infected tissue sample with a sodium hypochlorite solution to stimulate excystation of the sporocysts from the tissue. Thereafter, removal of the sodium hypochlorite solution and treatment of the sample with a cell culture media as the excystation fluid eliminates incubation and subsequent washing steps using expensive reagents. The excystation fluid contains substantially no chelating agents, proteins, enzymes or bile acids.

Abstract: A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.

Abstract: A safe and effective process for the oxidation of a primary or secondary alcohol to the corresponding aldehyde or ketone via the reaction of said alcohol with an anhydride solution of a 1,1,1-tri(C2-C4 alkanoyloxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one, and a composition useful in this process.

Abstract: The invention relates to certain stable vaccine compositions comprising a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof; at least one antigen; a dispersing agent; an adjuvant; a water soluble organic solvent; and saline or water or mixtures thereof. The invention further relates to stable compositions as described above of a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof, but without an antigen. The invention also relates to a method for preventing or controlling helminthiasis, infection by acarids and arthropod endo-and ectoparasites and bacterial and viral disease in warm-blooded animals by the parenteral administration of compositions of the invention. The invention further relates to a process for the preparation of the invention compositions.

Abstract: Mucosal adjuvants for vaccines contain water-soluble polyanionic polymers which have anionic constitutional units obtained from acids such as acrylic acid, methacrylic acid, maleic acid, fumaric acid, ethylsulphonic acid, vinylsulphuric acid, vinylsulphonic acid, styrenesulphonic acid, vinylphenylsulphuric acid, 2-methacryloyloxyethane sulphonic acid, 3-methacryloyloxy-2-hydroxypropanesulphonic acid, 3-methacryl amido-3-methylbutanoic acid, acrylamidomethylpropanesulphonic acid, vinylphosphoric acid, 4-vinylbenzoic acid, 3-vinyl oxypropane-1-sulphonic acid, N-vinylsuccinimidic acid, and salts of the foregoing. The polyanionic polymers may further have hydrophobic constitutional repeating units, such as alkylesters, cycloalkylesters, hydroxyalkylesters, ethers, glycols, aromatic groups and salts thereof. The adjuvants containing the polyanionic polymers are used in vaccines for the induction or enhancement of mucosal immune responses.

Abstract: The invention relates to vaccines which are suitable for the prevention of clostridial diseases of sheep (and lambs), providing an effective immunity for up to a year or more following a single injection or dose.

Abstract: Vaccine adjuvants comprising a liquid medium contain polymers with anionic constitutive repeating units and hydrophobic constitutive repeating units. Advantageously, the adjuvants are aqueous solutions of partially esterified polyacrylic acids. The novel adjuvants are highly stable, effective and have a relatively low level of local toxicity. Further, vaccines comprising such adjuvants and a process for producing them are described.

Abstract: The present invention is a saccharide-bsed matrix and the product resulting therefrom made from a maltodextrin feedstock subjected to conditions which induce flash flow of the maltodextrin so that the matrix possesses a physically- or chemically-altered structure from the feedstock. The present invention also includes a method of producing the matrix and of making products which take advantage of the unique properties of the matrix. Such products include, but are not limited to, unique colloidal-like dispersions and suspensions made from the matrix.

Abstract: Vaccine adjuvants comprising a sulpholipid polysaccharide in combination with an interface-forming constituent. The invention also provides a method for preparing a vaccine by emulsifying an aqueous solution of an antigen and a sulpholipid polysaccharide. The adjuvants are stable at high temperatures, and are at least as effective as conventional adjuvants. Their local toxicity, i.e. their reactogenicity, is generally lower than that of conventional adjuvants.

Abstract: The invention deals with the use of low temperature and low humidity conditions during the storage and shaping of “flash-dose” tablet compositions. The compositions may be rendered substantially non-amorphous before tablet formation.

Abstract: A method and apparatus provides for the formation of an encapsulated feedstock product matrix. A solid product matrix additive is spray ejected in a free-flow condition. The matrix additive is encapsulated in its free-flow condition with a matrix encapsulant. The encapsulant additive substantially solidifies in its free-flow condition to form the feedstock product matrix.

Abstract: A storage-stable combination of at least one &bgr;-lactam antibiotic and at least one &bgr;-lactam inhibitor compressed into tablet form having a hardness of greater than 30 KP is disclosed.

Abstract: A chewing gum composition for instant and extended release breath freshening has a gum base, at least one wetting agent, at least one immediate release flavor ingredient, and at least on encapsulation. The encapsulations include flavor encapsulations, metallic ion encapsulations, and organic substance encapsulations.

Abstract: The present invention is a unique process and apparatus for making a new matrix material called a shearform matrix which results in transformation of the morphology of a feedstock. The process is characterized by increasing the temperature of a nonsolubilized feedstock carrier to a point where it will undergo internal flow, followed by upwardly ejecting a stream of the feedstock and then subjecting it to disruptive fluid shear force which separates it into separate parts or masses which have a transformed morphology. The shearform matrix may include other ingredients such as oleaginous material and actives.